Furthermore, during the recovery phase from t = 60 to t = 120 min following a glucose challenge, blood glucose levels in the GLP1-ELP-FGF21 cohorts returned to near preinjection baselines, ~150 mg/dl, without evidence of hypoglycemia (Figs. 4C and 5D). This evidence concerns the gene FGF21 and Hypoglycemia.